- Home
- PYXS vs QNCX Comparison
PYXS vs QNCX Comparison
Compare PYXS & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYXS
- QNCX
- Stock Information
- Founded
- PYXS 2018
- QNCX 2012
- Country
- PYXS United States
- QNCX United States
- Employees
- PYXS N/A
- QNCX N/A
- Industry
- PYXS Biotechnology: Pharmaceutical Preparations
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PYXS Health Care
- QNCX Health Care
- Exchange
- PYXS Nasdaq
- QNCX Nasdaq
- Market Cap
- PYXS 101.1M
- QNCX 70.4M
- IPO Year
- PYXS 2021
- QNCX 2019
- Fundamental
- Price
- PYXS $1.54
- QNCX $1.59
- Analyst Decision
- PYXS Strong Buy
- QNCX Strong Buy
- Analyst Count
- PYXS 7
- QNCX 4
- Target Price
- PYXS $9.00
- QNCX $9.50
- AVG Volume (30 Days)
- PYXS 543.0K
- QNCX 126.5K
- Earning Date
- PYXS 03-20-2025
- QNCX 11-13-2024
- Dividend Yield
- PYXS N/A
- QNCX N/A
- EPS Growth
- PYXS N/A
- QNCX N/A
- EPS
- PYXS N/A
- QNCX N/A
- Revenue
- PYXS $16,146,000.00
- QNCX N/A
- Revenue This Year
- PYXS N/A
- QNCX N/A
- Revenue Next Year
- PYXS N/A
- QNCX N/A
- P/E Ratio
- PYXS N/A
- QNCX N/A
- Revenue Growth
- PYXS N/A
- QNCX N/A
- 52 Week Low
- PYXS $1.39
- QNCX $0.51
- 52 Week High
- PYXS $6.85
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- PYXS 43.02
- QNCX 38.88
- Support Level
- PYXS $1.50
- QNCX $1.51
- Resistance Level
- PYXS $1.67
- QNCX $1.67
- Average True Range (ATR)
- PYXS 0.09
- QNCX 0.13
- MACD
- PYXS 0.02
- QNCX -0.01
- Stochastic Oscillator
- PYXS 53.57
- QNCX 29.49
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing innovative precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics.